Recorlev Approved to Treat Endogenous Hypercortisolemia in Cushing Syndrome
The Food and Drug Administration (FDA) has approved Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative. Recorlev is…